Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MR-130A-01 Transdermal patch, 130A-01 patch
MR-130A-01 · 2 trials · 1 indication
A responder is a subject with no ovulation. A responder is a subject with no ovulation. Ovulation during treatment is defined as a Hoogland-Skouby score 5 or 6 in combination with fulfilment of Landgren criterion.
A responder is a subject with no ovulation. A responder is a subject with no ovulation. Ovulation during treatment is defined as a Hoogland-Skouby score 5 or 6 in combination with fulfilment of Landgren criterion.
| Arm | Type | Description |
|---|---|---|
| "regular": regular application without planned application errors | EXPERIMENTAL | - |
| Extended Period 1: regular application with planned application errors | EXPERIMENTAL | - |
| Extended Period 2: regular application with planned application errors | EXPERIMENTAL | - |
| Norelgestromin low dose 2.43mg 28/0 regimen non-Obese | EXPERIMENTAL | - |
| Norelgestromin mid dose 3.64mg 28/0 regimen non-Obese | EXPERIMENTAL | - |
| Norelgestromin high dose 4.86mg 28/0 regimen non-Obese | EXPERIMENTAL | - |
| Norelgestromin high dose 4.86mg 21/7 regimen non-Obese | EXPERIMENTAL | - |
| Norelgestromin mid dose 3.64mg 28/0 regimen Obese | EXPERIMENTAL | - |
| Norelgestromin high dose 4.86mg 28/0 regimen Obese | EXPERIMENTAL | - |
| Norelgestromin high dose 4.86mg 21/7 regimen Obese | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) | DRUG | MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) |
| MR-130A-01 Transdermal patch | DRUG | MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period. |
Inclusion Criteria: * 1\. Healthy, post-menarcheal and premenopausal women of age 18 to 35 years (inclusive) at screening examination. 2\. BMI ≥18.0 kg/m2 at screening examination. 3. Participants must be in good physical and mental health as determined by vital signs, medical history, and physi...
MR-130A-01 is an investigational transdermal contraceptive patch containing norelgestromin (NGMN). It is a small molecule in Phase 2 clinical development being studied for contraception in healthy female volunteers. Viatris Inc. (ticker VTRS) is developing the patch, which is designed to be applied to the skin rather than taken orally.
MR-130A-01 is being developed for contraception. Its clinical program evaluates ovulation inhibition as the basis for contraceptive activity in healthy female volunteers aged 18 years and older. The patch is investigational and has not been approved for contraceptive use.
Viatris Inc., which trades under the ticker VTRS, is the developer of MR-130A-01. The company is advancing the norelgestromin-containing contraceptive patch through Phase 2 clinical development.
MR-130A-01 is in Phase 2 clinical development. Two Phase 2 trials have been conducted in contraception: one completed dose-finding study and one currently recruiting study. The program has enrolled 228 participants in total across both trials, and the drug remains investigational.
MR-130A-01 has been studied in two Phase 2 trials. NCT06048536 was a completed dose-finding study of the contraceptive transdermal patch that enrolled 168 participants. NCT07365904 is a recruiting Phase 2 trial investigating ovulation inhibition for use as a contraceptive, with a planned enrollment of 60 participants in Germany.
Yes. MR-130A-01 is also known as the MR-130A-01 transdermal patch, the 130A-01 contraceptive patch, and the MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN). These names refer to the same investigational contraceptive patch developed by Viatris Inc.